Abstract: In an approach, a processor receives device identification information corresponding to at least one device local to a location of a transaction. A processor receives notification of an infected user. A processor determines that the infected user is associated with the transaction. A processor identifies a second user from the device identification information. A processor sends a notification to the second user.

Abstract: An apparatus, including: a first synchronizer configured to synchronize a frequency divider reset signal with a reference clock signal to generate a reference clock domain reset signal; a set of delay buffers configured to generate a set of delayed staggered reference clock domain reset signals based on the reference clock domain reset signal; a set of second synchronizers configured to synchronize the set of delayed staggered reference clock domain reset signals with a phase lock loop (PLL) clock signal to generate a set of PLL clock domain reset signals; a phase detector configured to generate a signal related to a phase difference between respective clocking edges of the reference clock signal and the PLL clock signal; a phase corrector configured to generate a select signal based on the phase difference signal; and a multiplexer configured to output one of the PLL clock domain reset signals based on the select signal.

Abstract: A method, computing system, and computer-program product for robust optimization of charging of a plurality of electric vehicles scheduled for charging at a charging station is provided. The charging station includes a plurality of chargers. In an embodiment, the method includes obtaining vehicle data and station data. Based thereon, it is determined if a set of EVs from amongst the plurality of EVs has failed to achieve a pre-defined target SoC, after a pre-defined charging duration. If the set of EVs has failed to achieve the pre-defined target SoC, a target power is computed. Further, the method includes adjusting at least one of the maximum power of each charger associated with charging of each EV from the set of EVs and the maximum power of the set of EVs as per the target power, to reach the target SoC of the set of EVs.

Abstract: A process can be used for preparing a polymer coated hard-shell capsule, filled with a fill containing a biologically active ingredient. The hard-shell capsule contains a body and a cap, and in a closed state, the cap overlaps the body in a pre-locked state or a final-locked state. The material of the body and cap contains an ethyl-, methyl-, or propyl-ether of cellulose, starch, or pullulan. The hard-shell capsule is coated with a coating layer, containing one or more anionic cellulose(s), ethyl cellulose, and/or one or more starches comprising at least 35% by weight of amylose, where the coating layer is present in an amount of about 1 to 5.8 mg/cm2. The process involves providing the polymer-coated hard-shell capsule in the pre-locked state to a capsule-filling machine, separating the body and the cap, filling the body with the fill, and rejoining the body and the cap in the final-locked state.

Abstract: An electronic gaming device including a memory and a processor is described. The processor is configured to provide an electronic game wherein return-to-player (RTP) in the electronic game is controlled based upon input amounts for the electronic game and, for at least one play of the electronic game where a secondary output amount is provided, store the secondary output amount in the memory as being associated with at least one input amount used for the at least one play. The processor is also configured to receive at least part of the secondary output amount to initiate a bonus play, determine an RTP for the bonus play based at least in part upon the at least one input amount used for the at least one play where the secondary output amount was provided, and cause the bonus play to be provided with the RTP for the bonus play.

Abstract: A process prepares a polymer-coated hard shell capsule, suitable as container for pharmaceutical or nutraceutical biologically active ingredients. The hard shell capsule can include a body and a cap. In the closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The hard shell capsule can be provided in the pre-locked state and spray-coated with a coating solution, suspension, or dispersion that includes a polymer or a mixture of polymers to create a coating layer which covers the outer surface of the hard shell capsule in the pre-locked state.

Abstract: Metal corrosion is a ubiquitous phenomenon costing the global economy, trillions of dollars annually. Conventional corrosion inhibitor compounds are either not so effective or require huge amount of inhibitor for adequate protection. The present disclosure addresses the problem of acid corrosion of iron and iron alloys which is relevant for a wide variety of industries such as oil and gas production and acid pickling etc. The technical solution provided in the present disclosure is a new corrosion inhibitor composition including Naphthalene-1-thiocarboxamide for iron and iron alloys in HCl media. This is specifically relevant for acid well stimulation in the oil and gas industries.

Abstract: The present invention relates to novel crystalline polymorphs of 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine monobenzenesulfonate, and to methods for their preparation. The invention further relates to pharmaceutical compositions containing one or more forms and optionally one or more suitable pharmaceutical carriers. The invention also relates to methods of using the crystalline polymorphs of the invention in the treatment of disease.

Abstract: This disclosure relates generally to methods and systems for screening and design of corrosion inhibitors. Conventional techniques in the art for predicting the inhibition efficiency of the molecule are not so accurate, where the inhibition efficiency is one of the important parameter for screening and design of corrosion inhibitors. In the present disclosure, the IE prediction model is developed by training a multi-task network model using the molecular descriptors of different classes of the molecules, and also the experimental conditions of the molecule. Further, a unique screening technique is disclosed that screens the molecules using various parameters including the inhibition efficiency of the molecule, an energy gap of the molecule, a synergistic effect of the molecules and an interaction energy of the molecules. Further the present disclosure allows to design a new molecule by making changes to the molecules that suits based on the end applications.

Abstract: A dosage form contains a biologically active ingredient for treating or preventing a disease in the animal or human body, where the treatment or prevention requires release of 50% or more of the biologically active ingredient in the small intestine within the pH range from 3 to 5.5. The dosage form contains: a) a core, containing the biologically active ingredient; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the intermediate coating layer, containing an enteric polymer. The relation of the alkaline agent to the enteric polymer is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? E ? C ? L ) .

Abstract: The present invention relates to novel crystalline polymorphs of 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine monobenzenesulfonate, and to methods for their preparation. The invention further relates to pharmaceutical compositions containing one or more forms and optionally one or more suitable pharmaceutical carriers. The invention also relates to methods of using the crystalline polymorphs of the invention in the treatment of disease.

Abstract: A process can be used for preparing a polymer coated hard-shell capsule, filled with a fill containing a biologically active ingredient. The hard-shell capsule contains a body and a cap, and in a closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The material of the body and the cap contains an ethyl-, methyl-, or propyl-ether of cellulose, starch, or pullulan. The hard-shell capsule is coated with a coating layer that covers the hard-shell capsule in the pre-locked state. The coating layer contains one or more (meth)acrylate copolymers, where the coating layer is present in an amount of about 1 to 5.8 mg/cm2. The process involves providing the polymer-coated hard-shell capsule in the pre-locked state to a capsule-filling machine, separating the body and the cap, filling the body with the fill, and rejoining the body and the cap in the final-locked state.

Abstract: Examples described herein include systems and methods for dynamically determining enrollment requirements and enrolling a user device into a management system. The systems and methods can differ based on the type and version of operating system executing on the user device. With some operating systems, enrollment can be completed through a single application that performs other functionality, such providing single-sign-on access to enterprise resources. With other operating systems, enrollment can be completed by pausing the first application and requiring installation of an agent application to complete enrollment. The determination of how and when to enroll a user device can be done automatically and can be based on an organizational group to which the user belongs.

Abstract: A dosage form contains a biologically active ingredient for treating or preventing a disease in the animal or human body, where treatment or prevention requires release of 50% or more of the biologically active ingredient in the small intestine within the pH range from 3 to 5.5. The dosage form contains: a) a core, containing the biologically active ingredient; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the ICL, containing an enteric polymer. The relation of alkaline agent to enteric polymer is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? ICL × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? ICL + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? ECL ) . The ? ICL ? has ? a ? thickness ? of ? about ? 22 ? ? ? m ? or ? more .

Abstract: A dosage form contains a biologically active ingredient for treating or preventing a disease in the animal or human body, where the treatment or prevention requires release of 50% or more of the biologically active ingredient in the small intestine within the pH range from 3 to 5.5. The dosage form contains: a) a core, containing the biologically active ingredient; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the intermediate coating layer, containing an enteric polymer. The relation of the alkaline agent to the enteric polymer is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? I ? C ? L + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? E ? C ? L ) .

Abstract: A dosage form contains a) a core, containing a biologically active ingredient, which is stable to a degree of at least 95% at a pH of 3 for 2 hours at 22° C.; b) an intermediate coating layer (ICL) onto or above the core, containing an alkaline agent; and c) an enteric coating layer (ECL) onto or above the intermediate coating layer, containing an enteric polymer. The relation in percent of the alkaline agent in the ICL to the enteric polymer in the ECL is 5 to 95% when calculated by the formula: quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? ICL × 100 ( quantity ? of ? alkaline ? agent ? in ? grams ? in ? the ? ICL + quantity ? of ? enteric ? polymer ? in ? grams ? in ? the ? ? ECL ) .

Abstract: A process can be used for preparing a polymer coated hard-shell capsule, filled with a fill containing a biologically active ingredient. The hard-shell capsule contains a body and a cap, and in a closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The material of the body and the cap contains an ethyl-, methyl-, or propyl-ether of cellulose, starch, or pullulan. The hard-shell capsule is coated with a coating layer that covers the hard-shell capsule in the pre-locked state. The coating layer contains one or more (meth)acrylate copolymers, where the coating layer is present in an amount of about 1 to 5.8 mg/cm2. The process involves providing the polymer-coated hard-shell capsule in the pre-locked state to a capsule-filling machine, separating the body and the cap, filling the body with the fill, and rejoining the body and the cap in the final-locked state.

Abstract: The present invention is related to a method of preparing a solid dosage form, comprising the steps of: a. preparing a lubricant consisting of at least one polyunsaturated fatty acid salt; b. adding the lubricant and ingredients for the solid dosage form to a mixer; c. optionally carrying out one or more of the following steps: granulation, drying and sizing, d. blending the contents of the mixer; and e. compressing or slugging the blended contents to produce a solid dosage form. Solid dosage forms prepared according to this method and the use of PUFA salts as lubricant in tableting applications for compression of solid components are further comprised by the present invention.

Abstract: The present invention is related to a method of preparing a solid dosage form, comprising the steps of: a) preparing a binder consisting of at least one polyunsaturated fatty acid salt; b) adding the binder and ingredients for the solid dosage form to a mixer; c) optionally carrying out one or more of the following steps: granulation, drying and sizing, d) blending the contents of the mixer; and e) compressing or slugging the blended contents to produce a solid dosage form wherein the binding parameter (BP) for the solid dosage form is at least 2 and is determined by: BP=H/C, wherein H is the tablet breaking force in Newton (N) and C is the compression force in kilo Newton (kN). Solid dosage forms prepared according to this method and the use of PUFA salts as binder in tableting applications for compression of solid components are further comprised by the present invention.

Abstract: The invention provides an improved down streaming process for production of polyunsaturated fatty acid salts suitable for tableting by direct compression.